Correlation Engine 2.0
Clear Search sequence regions

  • humans (1)
  • patients (9)
  • seizures (1)
  • vagus nerve (7)
  • Sizes of these terms reflect their relevance to your search.

    Vagus nerve stimulation (VNS) is used as a complementary therapy to pharmacological treatment in patients with refractory epilepsy. This study aims to evaluate the efficacy of VNS in reducing seizure frequency, severity, and duration; reducing the number of antiepileptic drugs administered; and improving patients' quality of life. We analysed the clinical progression of 70 patients with refractory epilepsy treated with VNS at Hospital Universitario de Alicante and Hospital Clínico de Valencia. Data were collected before and after the procedure. The difference in seizure frequency pre- and post-VNS was classified using the McHugh scale. Data were also collected on seizure duration and severity, the number of drugs administered, and quality of life. According to the McHugh classification, 12.86% of the patients were Class I, 44.29% were Class II, 40% were Class III, and the remaining 2.86% of patients were Class IV-V. A ≥ 50% reduction in seizure frequency was observed in 57.15% of patients. Improvements were observed in seizure duration in 88% of patients and in seizure severity in 68%; the number of drugs administered was reduced in 66% of patients, and 93% reported better quality of life. VNS is effective for reducing seizure frequency, duration, and severity and the number of antiepileptic drugs administered. It also enables an improvement in patients' quality of life. Copyright © 2019 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. All rights reserved.


    C Martorell-Llobregat, P González-López, E Luna, M Asensio-Asensio, R Jadraque-Rodríguez, G García-March, P Moreno-López. The role of vagus nerve stimulation in the treatment of refractory epilepsy: clinical outcomes and impact on quality of life. Neurologia (Barcelona, Spain). 2022 Jul-Aug;37(6):450-458

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 34088638

    View Full Text